News
GSGTF
3.100
NaN%
--
Weekly Report: what happened at GSGTF last week (1208-1212)?
Weekly Report · 5d ago
Weekly Report: what happened at GSGTF last week (1201-1205)?
Weekly Report · 12/08 09:53
Weekly Report: what happened at GSGTF last week (1124-1128)?
Weekly Report · 12/01 09:50
Weekly Report: what happened at GSGTF last week (1117-1121)?
Weekly Report · 11/24 09:54
Weekly Report: what happened at GSGTF last week (1110-1114)?
Weekly Report · 11/17 09:54
Weekly Report: what happened at GSGTF last week (1103-1107)?
Weekly Report · 11/10 09:52
Weekly Report: what happened at GSGTF last week (1027-1031)?
Weekly Report · 11/03 09:51
Weekly Report: what happened at GSGTF last week (1020-1024)?
Weekly Report · 10/27 09:54
Weekly Report: what happened at GSGTF last week (1013-1017)?
Weekly Report · 10/20 09:52
Weekly Report: what happened at GSGTF last week (1006-1010)?
Weekly Report · 10/13 09:54
Weekly Report: what happened at GSGTF last week (0929-1003)?
Weekly Report · 10/06 09:51
Weekly Report: what happened at GSGTF last week (0922-0926)?
Weekly Report · 09/29 09:52
Weekly Report: what happened at GSGTF last week (0915-0919)?
Weekly Report · 09/22 09:52
Weekly Report: what happened at GSGTF last week (0908-0912)?
Weekly Report · 09/15 11:48
Weekly Report: what happened at GSGTF last week (0901-0905)?
Weekly Report · 09/08 11:50
Weekly Report: what happened at GSGTF last week (0825-0829)?
Weekly Report · 09/01 11:44
Weekly Report: what happened at GSGTF last week (0818-0822)?
Weekly Report · 08/25 11:57
Weekly Report: what happened at GSGTF last week (0811-0815)?
Weekly Report · 08/18 11:48
Weekly Report: what happened at GSGTF last week (0804-0808)?
Weekly Report · 08/11 11:57
Weekly Report: what happened at GSGTF last week (0728-0801)?
Weekly Report · 08/04 12:00
More
Webull provides a variety of real-time GSGTF stock news. You can receive the latest news about Gensight Biologi through multiple platforms. This information may help you make smarter investment decisions.
About GSGTF
Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).